

July 21, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Mr. Daniel Crawford

**Re: Aptevo Therapeutics Inc.  
Registration Statement on Form S-1  
File No. 333-273067**

Dear Mr. Crawford:

Reference is made to our letter, filled as correspondence via EDGAR on July 14, 2023, in which we requested acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-273067) of Aptevo Therapeutics Inc. (the "Registration Statement") for 5:30 p.m., Eastern Time, on July 18, 2023, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at such time and we hereby formally withdraw our request for acceleration of the effective date of July 18, 2023. Please contact our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704 if you have any questions regarding this matter.

Very truly yours,

Aptevo Therapeutics Inc.

By: /s/ Marvin L. White  
Marvin L. White  
President and Chief Executive Officer

CC: SoYoung Kwon, Aptevo Therapeutics Inc.  
Daphne Taylor, Aptevo Therapeutics Inc.  
Sean M. Donahue, Paul Hastings LLP

---